New 'Living Drug' trial targets Tough-to-Treat blood cancers
NCT ID NCT07259070
First seen Jan 06, 2026 · Last updated Apr 06, 2026 · Updated 21 times
Summary
This early-stage study is testing a new type of CAR-T cell therapy, called BAFF-R CAR-T, for people with B-cell lymphomas that have come back or haven't responded to other treatments. Researchers will give the therapy at different doses to about 20 participants to check how safe it is and find the highest dose people can tolerate. They will also look for early signs that the treatment might help control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.